Breakthrough grant from the Carl Zeiss Foundation

We are excited to announce that the ImmuneMPS consortium has received a breakthrough grant from the Carl Zeiss Foundation. Led by Peter Loskill, the consortium combines the expertise of organoid engineers, immunologists, and oncologists in Tübingen. In addition to Florian, Juliane Walz, Yulia Skokowa, Julia Marzi, and Melanie Märklin are also part of the consortium. The consortium is planned for 6 years and will receive approximately 6,000,000 EUR in total funding. The multidisciplinary ImmuneMPS project aims to develop new organoid and organ-on-chip technologies to advance research on innovative immunotherapies and vaccines for cancer and infectious diseases. The ultimate goal of the consortium is to create integrated and connected organoid-chip systems that mimic different organs of the body, such as lymph nodes and tumor tissue, and their interactions.
More info: Carl Zeiss Foundation University Hospital Tübingen

The ImmuneMPS-Team (from left to right): Florian Wimmers, Juliane Walz, Peter Loskill, Julia Marzi, Melanie Märklin, Julia Skokowa (absent).

Cancer is one of the leading causes of death worldwide, and immunotherapy plays a crucial role in treatment. However, the complexity of the immune system and cancer makes creating effective and safe immunotherapies challenging. Using micro physiological systems, such as organoids and organ-on-chip technologies, allows for the safe simulation of these complex processes, potentially paving the way for innovative and personalized immunotherapeutic treatment methods and a better understanding of the interactions between cancer and the human immune system.